Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,770.00down ₹7.70 (0.43%)BSE ₹1,768.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,777.70.
2 Nov: open ₹1,770.00, high ₹1,776.20, low ₹1,722.00
52-week range of traded prices to 2 Nov 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,24,682 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.73
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 34,57,791
Sun Pharmaceutical Industries share news and announcements
1,453 announcements, routine notices left out, newest first. Page 23 of 30.
Apr 2013
Feb 2013
8 Feb · Results
Consolidated Results for the quarter ended on 31-DEC-2012 as follows: Net Sales of Rs. 285201 lacs for the quarter ending on 31-DEC-2012 against Rs. 214513 lacs for the quarter ending on 31-DEC-2011. Net Profit / (Loss) of of Rs. 88130 lacs for the quarter ending on 31-DEC-2012 against Rs. 66830 lacs for the quarter ending on 31-DEC-2011.8 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2012 as follows: Net Sales of Rs. 87573 lacs for the quarter ending on 31-DEC-2012 against Rs. 80568 lacs and Rs. 63121 lacs for the quarters ending on 30-SEP-2012 and 31-DEC-2011 respectively. Net Profit / (Loss) of Rs. 7422 lacs for the quarter ending on 31-DEC-2012 against Rs. 37062 lacs and Rs. 36523 lacs for the quarters ending on 30-SEP-2012 and 31-DEC-2011 respectively.1 Feb · Court Convened Meeting Updates
Jan 2013
23 Jan · Board meeting
Inter-alia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2012.
Dec 2012
Nov 2012
Oct 2012
22 Oct · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2012.5 Oct · Meeting
Company has received a letter of approval dated August 25, 2012 from the Register of Companies, Gujarat, Dadra & Nagar Haveli, granting extension of time for holding Annual General Meeting of the Company which ought to have been held on before September 30, 2012, upto November 15, 2012.4 Oct · Meeting
Sun Pharmaceuticals Industries Limited the Register of Members & Share Transfer Books of the Company will remain closed from November 02, 2012 to November 08, 2012 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on November 08, 2012.4 Oct · Raising of Funds
Board of Directors of the Company have, by Circular Resolution approved, subject to the approval of the Shareholders of the Company at the ensuing Annual General Meeting to be held on November 08, 2012 and subject to such other approvals as may be required. The raising of funds at an appropriate time through Domestic/ international offerings including to Indian or Foreign Institutional investors/Foreign Mutual Funds/Overseas Corporate Bodies/Foreigners/other Foreign parties/Indian Financial Institutions/Alternative Investment Funds/Qualified Institutional Buyers/Companies/individuals/other persons or investors, whether or not they are members of the Company, etc., pursuant to Section 81, 81(IA) of the Companies. Act. 1956 for an aggregate sum not exceeding Rs. 80 (Rupees Eighty ) billions.
Sep 2012
Aug 2012
10 Aug · Dividend
Board of Directors of the Company at its meeting held on August 10, 2012 has recommended the interim dividend of Rs.4.25 per Share of Re.1 each on Equity Shares of the Company for the year ended March 31, 2012.10 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 76061 lacs for quarter ending on 30-JUN-2012 against Rs. 68099 lacs for the quarter ending on 31-MAR-2012. Net Profit / (Loss) of Rs. 29263 lacs for the quarter ending on 30-JUN-2012 against Rs. 70200 lacs for the quarter ending on 31-MAR-2012.10 Aug · Results
Consolidated Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 265814 lacs for quarter ending on 30-JUN-2012 against Rs. 163572 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 79555 lacs for the quarter ending on 30-JUN-2012 against Rs. 50100 lacs for the quarter ending on 30-JUN-2011.6 Aug · Corporate action
Board has fixed the record date of August 16, 2012 for the purpose of payment of interim dividend for the year ended 31st March, 2012 in lieu of the earlier recommended proposed dividend for the year ended March 31, 2012 if such proposed interim dividend is declared at the ensuing Board Meeting. Further if interim dividend is declared by the Board ,it would be paid on or after August 22, 2012.
Jul 2012
30 Jul · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2012.
Jun 2012
May 2012
29 May · Management
Board of Directors of the Company at its meeting held on May 29, 2012 has appointed Mr. Israel Makov, a resident of Israel, as an additional Director on the Board of Directors of the Company. Further, Mr. Dilip Shanghvi has slepped down from the Chairmanship of the Company while continuing to remain the Managing Director of the Company and Mr. Israel Makov has been appointed as the Chairman of the Company at meeting of the Board of Directors of the Company held on May 29, 2012.29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2012 has recommended payment of dividend of Rs.4.25 per equity share of Re.1 each for the year ended March 31, 2012 subject to approval of members at ensuing Annual General Meeting.